compani announc result deliv revenu
net profit growth yoy rel weaker
sales/net profit grow sale net profit
miss estim
manufacturing/distribution/retail segment grew
yoy report strong
pharmaceut growth driven price increas
finish cardin dealth compani announc close
deal us mn februari start
consolid sinc estim cardin gener
bn sale account compani sale
maintain neutral tp estim
compani deliv net profit growth around organ
growth placement extra share
drive ep similar ratio remain neutral
compani due materi profit contribut supplement
drug would restrict next year
estimate pot chg tp
 chang prev ep
note note lead nation pharmaceut
group prc group primarili oper three busi segment pharmaceut
busi pharmaceut distribut suppli chain solut pharmaceut retail
click detail financi
compani announc result deliv revenu
net profit growth yoy rel weaker
sales/net profit grow sale net profit miss
estim manufactur net profit contribut
increas distribut net profit grow yoy
gross margin increas pp sell
expens increas pp total revenu admin
cost decreas pp total revenu
manufactur oper profit
increas yoy gross margin
improv pp yoy contribut rais asp low-pric
drug consolid manufactur subsidiari
major drug shenmai
impact restrict usag supplement drug compani
inject cefoten
hydrochlorid inject manufactur contract
inventori decreas see compani
supplement drug sale come pressur
strict polici implement
distribut oper profit
distribut sale increas yoy gross margin
improv pp improv gross margin driven higher ratio
direct sale hospit
indirect sale shrunk due implement two-invoic
system manag saw sale decreas bn indirect
sale expect impact bn given
provinc implement two-invoic system
compani announc close deal acquir
cardin china mn februari estim
cardin help gener compani sale cardin
sale bn rank china market
acquir cardin china distribut servic cover
provinc dtp drug store
revenu retail busi increas yoy gross
margin improv pp end compani
pharmaci within network number hospit
affili pharmaci increas compani becom
largest direct patient dtp servic provid acquir cardin
outlook valuat
estim compani deliv net profit growth
around organ growth remain neutral due
materi profit contribut supplement drug
restrict next year placement extra share
januari drive ep similar ratio
seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid
report singl factor make invest decis
rmb vs vs cost cost charl martineau pm univers toronto
compani mention price
serena shao certifi view express report accur reflect person view subject compani secur
part compens directli indirectli relat specif recommend view express report
price rate histori cah
signifi initi assumpt coverag
price rate histori shanghai pharmaceut hold co ltd
signifi initi assumpt coverag
price rate histori shanghai pharmaceut hold co ltd
signifi initi assumpt coverag
analyst respons prepar research report receiv compens base upon variou factor includ credit suiss total
revenu portion gener credit suiss invest bank activ
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base st ock total return rel analyst coverag univers
consist compani cover analyst within relev sector outperform repres attractiv neutral less attract
underperform least attract invest opportun octob canadian well european rate base stoc ks total return
rel analyst coverag univers consist compani cover analyst within rele vant sector outperform repres
attract neutral less attract underperform least attract invest opportun latin american asia stock exclud japan
australia rate base stock total return rel averag total return relev countri region benchmark india bse sensex index
prior octob canadian rate base stock absolut total return potenti curren share price rel
attract stock total return potenti within analyst coverag univers australian new zealand stoc ks expect total return calcul
includ roll dividend yield outperform rate assign greater equal under-perform less
equal neutral may assign overlap rate rang allow analyst assign rate put
context associ risk prior may rang outperform under-perform rate overlap ne utral threshold
oper juli
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
rate nr credit suiss equiti research invest rate view stock secur relat compani
time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate invest view
equiti secur compani relat product
volatil indic stock defin volatil stock price move month least past
month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or valuat
sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cover multipl sector
credit suiss distribut stock rate bank client
bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral nd under-perform close correspond
